These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 15537905)

  • 1. Anti-interleukin-12 antibody for active Crohn's disease.
    Mannon PJ; Fuss IJ; Mayer L; Elson CO; Sandborn WJ; Present D; Dolin B; Goodman N; Groden C; Hornung RL; Quezado M; Yang Z; Neurath MF; Salfeld J; Veldman GM; Schwertschlag U; Strober W;
    N Engl J Med; 2004 Nov; 351(20):2069-79. PubMed ID: 15537905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
    N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sargramostim for active Crohn's disease.
    Korzenik JR; Dieckgraefe BK; Valentine JF; Hausman DF; Gilbert MJ;
    N Engl J Med; 2005 May; 352(21):2193-201. PubMed ID: 15917384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab for the treatment of fistulas in patients with Crohn's disease.
    Present DH; Rutgeerts P; Targan S; Hanauer SB; Mayer L; van Hogezand RA; Podolsky DK; Sands BE; Braakman T; DeWoody KL; Schaible TF; van Deventer SJ
    N Engl J Med; 1999 May; 340(18):1398-405. PubMed ID: 10228190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
    Hommes DW; Mikhajlova TL; Stoinov S; Stimac D; Vucelic B; Lonovics J; Zákuciová M; D'Haens G; Van Assche G; Ba S; Lee S; Pearce T
    Gut; 2006 Aug; 55(8):1131-7. PubMed ID: 16507585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
    N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
    Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T
    Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
    Sandborn WJ; Gasink C; Gao LL; Blank MA; Johanns J; Guzzo C; Sands BE; Hanauer SB; Targan S; Rutgeerts P; Ghosh S; de Villiers WJ; Panaccione R; Greenberg G; Schreiber S; Lichtiger S; Feagan BG;
    N Engl J Med; 2012 Oct; 367(16):1519-28. PubMed ID: 23075178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.
    Feagan BG; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Koval J; Wong CJ; Hopkins M; Hanauer SB; McDonald JW
    N Engl J Med; 2000 Jun; 342(22):1627-32. PubMed ID: 10833208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.
    Feagan BG; Rochon J; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Gillies R; Hopkins M
    N Engl J Med; 1995 Feb; 332(5):292-7. PubMed ID: 7816064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab induction and maintenance therapy for Crohn's disease.
    Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
    N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
    Sandborn WJ; Feagan BG; Fedorak RN; Scherl E; Fleisher MR; Katz S; Johanns J; Blank M; Rutgeerts P;
    Gastroenterology; 2008 Oct; 135(4):1130-41. PubMed ID: 18706417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary study of growth hormone therapy for Crohn's disease.
    Slonim AE; Bulone L; Damore MB; Goldberg T; Wingertzahn MA; McKinley MJ
    N Engl J Med; 2000 Jun; 342(22):1633-7. PubMed ID: 10833209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
    Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
    Hanauer SB; Sandborn WJ; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh D; Panaccione R; Wolf D; Pollack P
    Gastroenterology; 2006 Feb; 130(2):323-33; quiz 591. PubMed ID: 16472588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.